Capecitabine CAS: 154361-50-9

CAS NO: 154361-50-9
Capecitabine
Chemical Name: Capecitabine
Molecular Formula: C15H22FN3O6
Formula Weight: 359.35
CAS No.: 154361-50-9
Description Review
Description

Capecitabine, also known by its brand name Xeloda, is a chemotherapy drug that is used to treat breast cancer, colorectal cancer, and other types of cancer. In this article, we will explore the properties, benefits, and potential side effects of Capecitabine.

Introduce this product:

Capecitabine is an orally administered chemotherapy drug that is used to treat several types of cancer, including breast cancer and colorectal cancer. It was first approved by the FDA in 1998 and has since become a commonly used treatment option for cancer patients.

Chemical name:

The chemical name of Capecitabine is 5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine.

Molecular formula:

The molecular formula of Capecitabine is C15H22FN3O6.

Formula weight:

The formula weight of Capecitabine is 359.35 g/mol.

CAS No:

The CAS number for Capecitabine is 154361-50-9.

Top ten keywords from Google and Synonyms:

  1. Chemotherapy drug
  2. Breast cancer treatment
  3. Colorectal cancer treatment
  4. Xeloda
  5. Cancer cells
  6. Metastatic cancer
  7. Chemotherapy side effects
  8. Chemotherapy dosing information
  9. Capecitabine mechanism of action
  10. Capecitabine safety

Health benefits of Capecitabine:

Capecitabine is an effective chemotherapy drug that has been shown to improve survival rates in patients with breast cancer and colorectal cancer. It works by inhibiting the growth of cancer cells, preventing them from replicating and spreading throughout the body.

Potential effects:

Capecitabine may cause a range of potential effects, including nausea, vomiting, fatigue, hair loss, and decreased appetite. It may also cause more serious side effects, such as low white blood cell count, increased risk of infection, and liver damage. Patients who experience any adverse effects should consult with their healthcare provider immediately.

Product mechanism:

Capecitabine works by being converted into the active drug fluorouracil (5-FU) in the body. 5-FU is then incorporated into DNA, leading to the disruption of DNA synthesis and ultimately causing cell death.

Safety:

Capecitabine is generally considered safe when used under the guidance of a healthcare professional. However, it can cause serious side effects, such as low white blood cell count, that may require medical attention. Patients should always inform their healthcare provider of any existing medical conditions or medications they are taking before starting treatment with Capecitabine.

Side effects:

The most common side effects of Capecitabine include nausea, vomiting, fatigue, hair loss, and decreased appetite. More serious side effects may occur, such as low white blood cell count, increased risk of infection, and liver damage. Patients should discuss potential side effects with their healthcare provider before starting treatment.

Dosing information:

The dosing of Capecitabine will vary depending on the type of cancer being treated and the patient's overall health. The drug is typically taken orally in pill form and is often given in combination with other chemotherapy drugs. Patients should follow their healthcare provider's instructions regarding dosing and administration of Capecitabine.

Conclusion:

Capecitabine is an effective chemotherapy drug that is used to treat breast cancer, colorectal cancer, and other types of cancer. While it can cause side effects, it has been shown to improve survival rates in patients with these types of cancer. Patients who are considering treatment with Capecitabine should discuss potential benefits and risks with their healthcare provider to determine if it is the best treatment option for them.

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code